Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

已完结 10 由 TI__ME 发布于 2026/10/28 16:24:08

DOI:10.1016/S0140-6736(21)00213-0
作者：Melanie Davies,?Louise F?rch,?Ole K Jeppesen,?Arash Pakseresht,?Sue D Pedersen,?Leigh Perreault,?Julio Rosenstock,?Iichiro Shimomura,?Adie Viljoen,?Thomas A Wadden,?Ildiko Lingvay
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for diabetes treatment)

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierComprehensive comparison of physicochemical properties, volatile flavor compounds and functional activities of double protein yogurt with different soymilk and cow milk additions